NCT00044525View on ClinicalTrials.gov

Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL

Enrollment

82

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

February 29, 2004

Study Completion Date

February 29, 2004

Conditions

Breast NeoplasmsBreast Cancer, Metastatic

Interventions

DRUG

BAY59-8862 (Cytotoxic Taxane)

1 h intravenous infusion every 3 weeks

Trial Locations (22)

5001

Aarau

10117

Berlin

12100

Cuneo

13900

Biella

15123

Marousi

20089

Rozzano

24047

Treviglio

31096

Haifa

33100

Udine

43100

Parma

47100

Forlì

52621

Tel Litwinsky

64239

Tel Aviv

70376

Stuttgart

78306

Ashkelon

07740

Jena

711 10

Heraklion

10-228

Olsztyn

00-909

Warsaw

02-781

Warsaw

NW3 2QG

London

SW3 6JJ

London

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Bayer

INDUSTRY